Continuous positive airway pressure treatment: Effect on serum lipids in patients with obstructive Sleep Apnoea

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 231-238

  Michailidis, Vassileios ^a   Steiropoulos, Paschalis ^a   Nena, Evangelia ^a   Papanas, Nikolaos ^a   Maltezos, Efstratios ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cholesterol; Continuous positive airway pressure; Lipid profile; Obstructive sleep apnoea; Triglycerides

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84856616348     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010231     Document Type: Review

References (51)

1. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-43.
2. McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156-78.
3. Malhotra A, Ayas NT, Epstein LJ. The art and science of continuous positive airway pressure therapy in obstructive sleep apnea. Curr Opin Pulm Med 2000; 6: 490-5.
4. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; 3: CD001106.
5. Gordon P, Sanders MH. Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome. Thorax 2005; 60: 68-75.
6. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132: 843-51.
7. Steiropoulos P, Kotsianidis I, Nena E, et al. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep 2009; 32: 537-43.
8. Weaver TE, Kribbs NB, Pack AI, et al. Night-to-night variability in CPAP use over the first three months of treatment. Sleep 1997; 20: 278-83.
9. Zimmerman ME, Arnedt JT, Stanchina M, Millman RP, Aloia MS. Normalization of memory performance and positive airway pressure adherence in memory-impaired patients with obstructive sleep apnea. Chest 2006; 130: 1772-8.
10. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995; 8: 222-9.
11. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100-5.
12. Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDLcholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am 2009; 38: 45-78.
13. Leren P, Foss PO, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980; 2: 2-4.
14. Lowenstein J. Effects of prazosi n on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease, hypertension and other risk factors, Milan. Am J Cardiol 1984; 53: 21A-23A.
15. Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243-60.
16. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706.
17. Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-63.
18. Li J, Grigoryev DN, Ye SQ, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 2005; 99: 1643-8.
19. Kono M, Tatsumi K, Saibara T, et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-92.
20. Börgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006; 27: 121-7.
21. Can M, Açikgöz S, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129: 233-7.
22. Iesato K, Tatsumi K, Saibara T, et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J 2007; 71: 1293-8.
23. Tan KC, Chow WS, Lam JC, et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377-82.
24. Newman AB, Nieto FJ, Guidry U, et al. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001; 154: 50-9.
25. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.
26. Zgierska A, Górecka D, Radzikowska M, et al. Obstructive sleep apnea and risk factors for coronary artery disease. Pneumonol Alergol Pol 2000; 68: 238-46.
27. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-41.
28. Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000; 16: 128-33.
29. Ip MS, Lam KS, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-6.
30. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007; 175: 190-5.
31. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-7.
32. Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999; 100: 706-12.
33. Buechner NJ, Zidek W, Eer M, Haske M, Sanner BM. Obstructive sleep apnea syndrome. Effects of therapy on dyslipidemia. Somnologie 2001; 5: 97-102.
34. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004; 59: 777-82.
35. Dorkova Z, Petrasova D, Molcanyiova A, Popovnakova M, Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-92.
36. Barceló A, Barbé F, de la Peña M, et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008; 63: 946-50.
37. Oktay B, Akbal E, Firat H, Ardiç S, Kizilgun M. CPAP treatment in the coexistence of obstructive sleep apnea syndrome and metabolic syndrome, results of one year follow up. Acta Clin Belg 2009; 64: 329-34.
38. Cuhadaroglu C, Utkusavas A, Ozturk L, Salman S, Ece T. Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. Lung 2009; 187: 75-81.
39. Davies RJ, Turner R, Crosby J, Stradling JR. Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring; their comparison with matched controls and response to treatment. J Sleep Res 1994; 3: 180-5.
40. Barceló A, Barbé F, Llompart E, et al. Effects of obesity on Creactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004; 117: 118-21.
41. Al-Shaer M, Shammas N, Lemke J, et al. CPAP does not reduce high-sensitivity C-Reactive protein in patients with coronary artery disease and obstructive sleep apnea. Int J Angiol 2005; 129-32.
42. Lattimore JL, Wilcox I, Skilton M, Langenfeld M, Celermajer DS. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 2006; 61: 491-5.
43. Kitahara Y, Hattori N, Yokoyama A, Nakajima M, Kohno N. Effect of CPAP on brachial-ankle pulse wave velocity in patients with OSAHS: an open-labelled study. Respir Med 2006; 100: 2160-9.
44. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-74.
45. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176: 706-12.
46. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720-7.
47. Li C, Zhang XL, Liu H, Wang ZG, Yin KS. Association among plasma interleukin-18 levels, carotid intima-media thickness and severity of obstructive sleep apnea. Chin Med J (Engl) 2009; 122: 24-9.
48. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15: 479-89.
49. Steiropoulos P, Papanas N, Nena E, Maltezos E, Bouros D. Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev 2010; 6: 156-66.
50. Steiropoulos P, Papanas N, Nena E, et al. Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: does adherence to CPAP treatment improve glycemic control? Sleep Med 2009; 10: 887-91.
51. Steiropoulos P, Papanas N, Maltezos E, Bouros D. Is there a metabolic effect of continuous positive airway pressure in sleep apnoea? Adherence should not be underestimated. Eur Respir J 2009; 34: 1209-10.